CSIMarket
 
Intra cellular Therapies Inc   (NASDAQ: ITCI)
Other Ticker:  
 
 
Price: $127.0100 $-0.11 -0.087%
Day's High: $127.26 Week Perf: -0.14 %
Day's Low: $ 127.01 30 Day Perf: 52.6 %
Volume (M): 1,548 52 Wk High: $ 128.00
Volume (M$): $ 196,548 52 Wk Avg: $78.84
Open: $127.24 52 Wk Low: $62.78



 Market Capitalization (Millions $) 13,434
 Shares Outstanding (Millions) 106
 Employees 202
 Revenues (TTM) (Millions $) 614
 Net Income (TTM) (Millions $) -86
 Cash Flow (TTM) (Millions $) 365
 Capital Exp. (TTM) (Millions $) 1

Intra Cellular Therapies Inc
Intra cellular Therapies Inc (ITCI) is a biopharmaceutical company that is focused on the discovery and development of molecular drugs that target the central nervous system (CNS). The company's mission is to develop innovative therapies that can improve the lives of patients with serious neurological and psychiatric disorders. The company is based in New York and was founded in 200

ITCI's therapies are based on the science of phospholipid signaling. Phospholipids are important molecules that are present in the membranes of cells. They play a key role in cell to cell communication by signaling within and between cells. ITCI has developed drug candidates that target specific pathways in the brain that are controlled by these signaling molecules. These pathways have been implicated in a range of psychiatric and neurological disorders including schizophrenia, bipolar disorder, depression, and Alzheimer's disease.

The company's lead drug candidate is Lumateperone, which is an oral medicine that has been developed for the treatment of schizophrenia. It is designed to balance the activity of neurotransmitters in the brain, which can help to reduce the symptoms of schizophrenia, such as hallucinations and delusions. Lumateperone has completed three phase-3 clinical trials, and the results have been positive. The drug was granted FDA approval in December 2019.

ITCI has also developed other drug candidates for the treatment of major depressive disorder, bipolar disorder, and other neurological conditions such as Alzheimer's disease. The company has a deep pipeline of CNS-focused drug candidates, which is supported by a strong intellectual property portfolio.

In addition to its drug development efforts, ITCI is also engaged in research and development of digital therapeutics. These are software-based interventions that are designed to improve patient outcomes by providing targeted support, education, and engagement. ITCI is exploring the potential for digital therapeutics to complement its drug therapies.

In summary, Intra cellular Therapies Inc is a biopharmaceutical company that is focused on the discovery and development of innovative therapies for serious neurological and psychiatric disorders. The company has developed drug candidates that target specific pathways in the brain that are controlled by phospholipid signaling. These therapies have the potential to improve patient outcomes and fill unmet medical needs in this area.


   Company Address: 135 Route 202/206, Suite 6 Bedminster 7921 NJ
   Company Phone Number: 440-9333   Stock Exchange / Ticker: NASDAQ ITCI


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV        0.38% 
ALKS        2.63% 
BMRN        2.39% 
BMY   -7.48%    
LLY        4.74% 
PFE   -0.77%    
• View Complete Report
   



Merger and Acquisition

Intra-Cellular Therapies Expands Portfolio with Strategic Acquisition, Reports Promising CAPLYTA Study Results at ACNP Annual Meeting

Published Mon, Jan 13 2025 11:32 AM UTC

Breaking News: Intra-Cellular Therapies Announces A...

Clinical Study

Intra-Cellular Therapies Reports Key Findings from CAPLYTA MDD Phase 3 Studies at ACNP Annual Meeting,

Published Mon, Dec 30 2024 1:22 AM UTC

Intra-Cellular Therapies Inc recently presented compelling new data from its CAPLYTA (lumateperone) adjunctive therapy programme for major depressive disorder (MDD) at the annual meeting of the American College of Neuropsychopharmacology (ACNP). The presentations elaborated on topline results from pivotal studies, designated Studies 501 and 502, which explore the efficacy of...

Clinical Study

Augmenting Psychiatric Care Lumateperone Demonstrates Promising Results in Schizophrenia and Major Depress...

Published Tue, Nov 5 2024 12:00 PM UTC

Abstract: The recent advancements in the pharmacological management of schizophrenia and major depressive disorder (MDD) mark a significant milestone in psychiatric medicine. Lumateperone, marketed as CAPLYTA, has demonstrated promising outcomes in two pivotal phase 3 clinical trials. The first trial focused on its role as a maintenance treatment for schizophrenia, while the...

Intra Cellular Therapies Inc

Intra Cellular Therapies Inc. Struggles to Achieve Profitability Despite Rapid Revenue Growth in Fiscal Q3 2024

Financial Analysis of Intra Cellular Therapies Inc for Q3 2024 Intra Cellular Therapies Inc (ITCI) has reported its financial results for the third quarter of fiscal year 2024, revealing a complex picture of revenue growth coupled with continued losses. This article seeks to dissect these financial figures, placing them within the broader context of the pharmaceutical industry and market performance. Key Financial Results1. Earnings Per Share (EPS): - ITCI reported a loss of $-0.25 per share for the financial interval ending September 30, 2024. This represents a decline compared to the loss of $-0.16 per share in the previous quarter.

Management Changes

Intra-Cellular Therapies Strengthens Leadership Team with New CFO Appointment

Published Wed, Aug 7 2024 11:41 AM UTC



Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a renowned biopharmaceutical company specializing in the development and commercialization of therapeutics for central nervous system (CNS) disorders, has recently announced the appointment of Sanjeev Narula as their Executive Vice President and Chief Financial Officer. With this strategic move, ITCI aims to reinforce ...







Intra Cellular Therapies Inc's Segments

  Intra Cellular Therapies Inc Outlook

On October 30 2024 the Intra Cellular Therapies Inc provided following guidance

Intra-Cellular Therapies Inc. has recently released its financial results for the third quarter of 2024, along with a corporate update that signals a positive trajectory for the company. Notably, the company has raised its sales guidance for Caplyta for the year 2024, indicating optimism about its market performance, although specific figures regarding the adjusted guidance were not disclosed in the announcement.

During the third quarter of 2024, Intra-Cellular Therapies reported impressive net product sales for Caplyta, totaling $175.2 million. This marks a remarkable 39% increase compared to the $125.8 million reported during the same quarter in 2023, highlighting the growing demand and acceptance...





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com